- Aardvark reported progress around its lead candidate ARD-101, which is being developed for hyperphagia associated with Prader-Willi Syndrome and is positioned as a potential treatment option in an area with limited alternatives.
- The company said it voluntarily paused enrollment and dosing in the Phase 3 HERO and related open-label extension trials after reversible cardiac observations in a healthy volunteer study, a development that could affect timelines and near-term competitive positioning.
- A second program, ARD-201, was described as a planned fixed-dose combination aimed at obesity and obesity-related conditions, and its Phase 2 studies were also paused as the company assesses implications for the broader portfolio.
- Separately, Aardvark filed for a shelf registration covering up to USD 400.0 million of securities, including an at-the-market program of up to USD 150.0 million, which could provide financing flexibility while clinical plans are reviewed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-119973), on March 23, 2026, and is solely responsible for the information contained therein.
Comments